If value-based care represents the future of healthcare, it needs a better definition, attendees at an HHS forum said.
Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales
Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
One analyst said he expects that the change in label "will meaningfully commercially impair Viekira Pak sales."
The drugmaker aims to differentiate its type-2 diabetes drug in the competitive GLP-1 receptor agonist class.
Attention turns to Valeant, which is facing subpoenas from two attorneys general who are seeking information about the drugmaker's patient-assistance, drug-pricing and drug-distribution practices.
Sanofi's Aubagio reduces brain volume loss; cancer specialists avoid pricey cancer meds; analysis says placebo effect is on the rise
The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.